Anyone with access to the right data can tell you which technologies and medical specialties are commanding the highest valuations from venture capital investors. But what would it be worth to know which companies will be commanding the top prices in the next year? A survey of more than a dozen VCs—who participated with a promise of anonymity—with money to invest draws a very clear picture about what investment opportunities they might find worth fighting over and the areas they'll ignore.
Among areas they favor are ophthalmology, atrial fibrillation, endogastric devices, neurostimulation, heart valves, and molecular diagnostics. In some cases, like atrial fibrillation and heart valves, venture investors were impressed both by the potential market and the actual returns realized from high-profile acquisitions in each space. Last year, Medtronic PLC acquired atrial fibrillation company Ablation Frontiers Inc. (now Medtronic Ablation Frontiers LLC) for $225 million plus earn-outs. [See Deal] That came just a few weeks before Medtronic announced its $700 million acquisition of aortic valve maker CoreValve Inc. (now Medtronic CoreValve LLC)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?